高级搜索

自体DC/CIK联合厄洛替尼维持治疗老年晚期非小细胞肺癌的临床疗效分析

何志惠, 洪 涛, 苏群豪, 曾江正, 桑圣刚

何志惠, 洪 涛, 苏群豪, 曾江正, 桑圣刚. 自体DC/CIK联合厄洛替尼维持治疗老年晚期非小细胞肺癌的临床疗效分析[J]. 肿瘤防治研究, 2014, 41(06): 645-648. DOI: 10.3971/j.issn.1000-8578.2014.06.030
引用本文: 何志惠, 洪 涛, 苏群豪, 曾江正, 桑圣刚. 自体DC/CIK联合厄洛替尼维持治疗老年晚期非小细胞肺癌的临床疗效分析[J]. 肿瘤防治研究, 2014, 41(06): 645-648. DOI: 10.3971/j.issn.1000-8578.2014.06.030
shu
HE Zhihui, HONG Tao, SU Qunhao, ZENG Jiangzheng, SANG Shenggang. Clinical Effects of Maintenance Therapy Combining Autologous DC/CIK and Erlotinib on Elderly Patients with Advanced Non-small Cell Lung Cancer[J]. Cancer Research on Prevention and Treatment, 2014, 41(06): 645-648. DOI: 10.3971/j.issn.1000-8578.2014.06.030
Citation: HE Zhihui, HONG Tao, SU Qunhao, ZENG Jiangzheng, SANG Shenggang. Clinical Effects of Maintenance Therapy Combining Autologous DC/CIK and Erlotinib on Elderly Patients with Advanced Non-small Cell Lung Cancer[J]. Cancer Research on Prevention and Treatment, 2014, 41(06): 645-648. DOI: 10.3971/j.issn.1000-8578.2014.06.030
shu

自体DC/CIK联合厄洛替尼维持治疗老年晚期非小细胞肺癌的临床疗效分析

  • 1.570102海口，海南医学院附属医院血液肿瘤科；2.海南医学院热带与检验学院

基金项目: 海南省重点科技计划资助项目（ZDXM20100046）
详细信息
    作者简介:

    何志惠（1971-），女，硕士，副主任医师，主要从事恶性肿瘤的基础及临床研究

    通讯作者:

    桑圣刚，E-mail：939523232@qq.com

  • 中图分类号: R734.2

Clinical Effects of Maintenance Therapy Combining Autologous DC/CIK and Erlotinib on Elderly Patients with Advanced Non-small Cell Lung Cancer

  • 1.Department of Hematology and Oncology, The Affiliated Hospital of Hainan Medical College, Haikou 570102, China;2.School of Tropical and laboratory of Hainan Medical University

HTML全文

    摘要
  • 摘要: 目的 观察自体DC/CIK联合厄洛替尼（商品名：特罗凯）维持治疗老年晚期非小细胞肺癌患者的临床意义。方法 将经病理学或细胞学确诊的Ⅲb、Ⅳ期老年（65~85岁）晚期非小细胞肺癌患者42例，经一线含铂两药方案化疗4周期后，疗效达到稳定或以上患者随机分为两组。一组（联合组）给予特罗凯及自体DC/CIK生物免疫治疗，另一组(单药组)给予特罗凯单药治疗，每月复查评估近期疗效、无肿瘤进展时间及生活质量。结果 两组的疾病控制率分别是85.7%和71.4%（χ2=8.75，P=0.015）。无肿瘤进展时间分别为5.23月、3.57月（P=0.017）。治疗后两组的生活质量均有改善（P=0.001，P=0.008），联合组更为显著（P=0.033）。两组的不良反应主要是皮疹及腹泻，但均能耐受,未作特殊处理自行缓解。结论 特罗凯联合自体DC/CIK维持治疗老年晚期非小细胞肺癌能更好地改善患者生活质量，提高疗效及延长生存期。

     

    Abstract: Objective To evaluate the clinical effects of maintenance therapy combining of autologous dentritic cells ( DC ) and cytokine induced killer cells ( CIK cells ) and erlotinib on elderly patients with advanced non-small cell lung cancer ( NSCLC ). Methods Fourty-two elderly patients (65-85 years old) with Stage-Ⅲb and Ⅳ NSCLC underwent 4 cycles of platinum-based two-drug chemotherapy and achieved stable status or much better condition. The patients were randomized into 2 groups, i.e., combination therapy group, which received a biological immunotherapy combining erlotinib and autologous DC/CIK cells, and erlotinib therapy group, which was given erlotinib therapy alone. Effi cacy, progression-free survival(PFS) and quality of life were evaluated every month. Results The disease control rates of two groups were 85.7% and 71.4%(χ2=8.75,P=0.015), respectively. The PFS of both groups were 5.23 and 3.57 months respectively(P=0.017). The quality of life were both improved(P=0.001，P=0.008),especially to the combination group(P=0.033). The untoward reactions of both groups were tolerable rashes and diarrhea. Conclusion The maintenance treatment combining erlotinib and autologous DC/CIK cells can improve quality of life, enhance effi cacy and prolong survival time of elderly patients with advanced NSCLC.

     

    • HTML全文
    • 参考文献(11)
  • [1] Pao W, Girard N. New driver mutations in non-small-cell lung cancer[J]. Lancet Oncol,2011,12(2):175-80.
    [2] Paz-Ares LG，de Marinis F， Dediu M，et al．PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous nonsmall- cell lung cancer[J]. J Clin Oncol,2013,31(23);2895-902.
    [3] Han BL.Review 2009:Advances in medical treatment of lung cancer[J].Zhongguo Chu Fang Yao,2010,96(3):40-2.[ 韩 宝惠.回顾2009年: 肺癌内科治疗进展[ J ] .中国处方药， 20 10,96(3):40-2.]
    [4] Introna M, Borleri G, Conti E,et al. Repeated infusions of donorderived cytokine-induced killer cells in patients relapsing after allogeneic stem cell transplantation: a phase I study[J]. Haematologica,2007, 92(7):952-9.
    [5] Li H, Wang C, Yu J, et al. Dendritic cell-activated cytokine-induced killer cells enhance the anti-tumor effect of chemotherapy on nonsmall cell lung cancer in patients after surgery[J].Cytotherapy,200 9, 11(8):1076-83.
    [6] Sumpter K, Harper-Wynne C, Cunningham D, et al. Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF[J]. Br J Cancer,2005, 92 (11) :1976-83.
    [7] Shi SB, Li CH, Tang XY, et al. The effects of maintenance therapy combining DC/CIK and erlotinib on patients with advanced non-small cell lung cancer[J]. Zhongguo Zhong Liu Lin Chuang,2012,39(3):160-2．[时圣彬,李春华,唐晓勇,等.厄洛替 尼联合DC/CIK在晚期非小细胞肺癌维持治疗中的作用[J].中国 肿瘤临床,2012,39(3):160-2.]
    [8] Cappuzzo F, Ciuleanu T, Stelmakh L, et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised，placebo- controlled phase 3 study[J]. Lancet Oncol, 2010,11(6):521-9.
    [9] Chen FX, Liu JQ, Zhang NZ, et a1．Clinical observation on adoptive immunotherapy with autologous cytokine induced killer cells for advanced malignant tumor[J]. Ai Zheng,2002,21(7):797-801．[陈复兴,刘军权,张南征,等.自身细 胞因子诱导的杀伤细胞过继性免疫治疗恶性肿瘤的临床观察 [J] 癌症,2002,21(7):797-801.]
    [10] Sangiolo D, Martinuzzi E, Todorovic M, et al. Alloreactivity and anti-tumor activity segregate within two distinct subsets of cytokine-induced killer(CIK) cells: implications for their infusion across major HLA barriers[J]. Int Immunol,2008, 20(7):841-8.
    [11] Oosterwijk E, Divgi C, Bander NH. Active and passive immunotherapy：vaccines and antibodies[J]．BJU Int,2007,99(5 Pt B) :1301-4.
    • 相关文章
    • 施引文献
    • 资源附件(0)
计量
  • 文章访问数:  1329
  • HTML全文浏览量:  273
  • PDF下载量:  598
  • 被引次数: 0
出版历程
  • 收稿日期:  2013-05-18
  • 修回日期:  2013-07-03
  • 刊出日期:  2014-06-24

目录

摘要
HTML全文
    参考文献(11)
    相关文章
    施引文献
    资源附件(0)

    /

    返回文章
    返回

    下载中心

    友情链接

    联系我们

    地址：武汉市洪山区卓刀泉南路116号（430079）

    电话：027－87670126

    Email：zlfzyjzz@vip.163.com

    This work is licensed under a Creative Commons Attribution 3.0 License.

    邮件订阅 RSS
    总访问量：11646824 今日访问：14173

    版权所有 © 《肿瘤防治研究》编辑部 鄂公网安备 42011102005013号 鄂ICP备2022015867号

    本系统由北京仁和汇智信息技术有限公司开发  百度统计

    x 关闭 永久关闭